A Real-World Prognosis in Idiopathic Pulmonary Fibrosis: A Special Reference to the Role of Antifibrotic Agents for the Elderly
Department of Respiratory Medicine, Kyorin University School of Medicine, Mitaka City 181-8611, Japan
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2023, 12(10), 3564; https://doi.org/10.3390/jcm12103564
Submission received: 25 March 2023
/
Revised: 5 May 2023
/
Accepted: 17 May 2023
/
Published: 19 May 2023
(This article belongs to the Section Respiratory Medicine)
Abstract
:Background: Idiopathic pulmonary fibrosis (IPF) is the most common and severe form of idiopathic interstitial pneumonia, and its prevalence increases with age. In the era of pre-antifibrotic agents, the median survival time of Japanese patients with IPF is 35 months, with a 5-year survival rate in western countries ranging from 20% to 40%. The prevalence of IPF is highest in elderly patients aged ≥75 years; however, the efficacy and safety of long-term use of pirfenidone and/or nintedanib are not fully understood. Objective: This study aimed to determine the efficacy and safety of the sole use of antifibrotic agents (pirfenidone or nintendanib) for IPF in the elderly. Method: We retrospectively reviewed patients with IPF who were diagnosed and treated with either pirfenidone or nintedanib in our hospital between 2008 and 2019. We excluded patients with the subsequent use of both antifibrotic agents. We examined the survival probability and frequency of acute exacerbation, with focus on long-term use (≥1 year), elderly patients (≥75 years of age), and disease severity. Results: We identified 91 patients with IPF (male to female ratio: 63 to 28, age 42 to 90 years). The numbers of patients with disease severity classified by JRS (I/II/III/IV) and GAP stage (I/II/III) were (38/6/17/20) and (39/36/6), respectively. The survival probabilities were comparable between the elderly (n = 46) and non-elderly groups (n = 45, p = 0.877). After the initiation of antifibrotic agents, the cumulative incidence ratio of acute exacerbation of IPF was significantly lower in the early stage (GAP stage I, n = 20) than in the progressive stage of disease (GAP stages II and III, n = 20, p = 0.028). A similar trend was noted in the JRS disease severity classification (I, II vs. III, IV) (n = 27 vs. n = 13, p = 0.072). In the long-term treatment (≥1 year) group (n = 40), the survival probabilities at 2 and 5 years after treatment initiation were 89.0% and 52.4%, respectively, which did not reach the median survival rate. Conclusions: Even in elderly patients (≥75 years of age), antifibrotic agents demonstrated positive effects on survival probability and the frequency of acute exacerbation. These positive effects would be improved for earlier JRS/GAP stages or long-term use.
1. Introduction
Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic progressive fibrosing interstitial pneumonia of unknown cause that occurs in adults. Recently, Kondoh et al. reported that the nationwide number of IPF patients in Japan was estimated to be 34,040 (mean age: 73 years, percentage of men: 73%), and the prevalence was 27 per 100,000 people [1], which was higher than that of one prefecture (10.0 per 100,000 population) using clinical data (2003–2007) [2]. The prognosis of IPF is poor, with a median survival of 2–3 years if left untreated [3]. Moreover, acute exacerbation therapies [4] have a median survival rate following an AE of approximately 3–4 months [5]. Homma et al. reported that the annual incidence of acute exacerbation (AE) was approximately 10% between 2010 and 2018, based on a Japanese claims database (April 2008–March 2019) from acute care hospitals [6].
The use of antifibrotic agents (pirfenidone and nitedanib) can decrease the frequency of AE of IPF [7], even with short-term use in the perioperative phase [8]; however, little is known about the significance of antifibrotic agents in elderly patients (≥75 years of age) and their effect on survival in long-term use. The aim of this study is to clarify the efficacy and safety of antifibrotic agents (pirfenidone or nintendanib) for IPF in the elderly.
2. Materials and Methods
We retrospectively reviewed the medical records of patients with IPF who were treated with antifibrotic agents (pirfenidone or nintedanib) and visited our hospital between 2008 and 2019. Among the antifibrotic drugs, pirfenidone was administered at a daily dose of 600–1800 mg, while nintedanib was administered at a daily dose of 200 mg or 300 mg. IPF was diagnosed according to international guidelines [9]. High-resolution chest computed tomography was performed for diagnosis in all patients. This study excluded patients administered both antifibrotic medications. Clinical information obtained at the time of diagnosis included disease severity according to the Japanese Respiratory Society (JRS) classification or Gender, Age, and Physiology (GAP) stage, serum markers (Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D)), respiratory function tests, age, sex, and body mass index. The definition of an elderly patient is over 75 years old, and we compared the findings between elderly (≥75 years of age) and non-elderly (≤74 years of age) patients. Clinical courses such as survival probability and acute exacerbation from the first visit to our hospital (at the time of diagnosis) and the timing of initial treatment with antifibrotic drugs to those events were also recorded.
Statistical Analysis
Numerical data were evaluated for normal distribution and equal variance using Kolmogorov–Smirnov and Levene median tests, respectively. Categorical data are presented as percentages of the total or numerically, as appropriate. Statistical comparisons of non-parametric data were performed using Mann–Whitney U tests. Categorical data were compared using Pearson’s chi-square tests. All tests were two-sided, with statistical significance set at p < 0.05. Based on the extracted parameters, we performed Cox regression analysis, Kaplan–Meier analysis, and log-rank analysis. The data were analyzed using IBM SPSS Statistics for Windows, version 25.0. This study was approved by the ethics committee of Kyorin University Hospital (approval number: 968, H29-044).
3. Results
We enrolled 91 patients with IPF, comprising 46 elderly and 45 non-elderly patients. The male-to-female ratio was approximately 2:1. The patient ages ranged from 42 to 90 years, with median ages in the elderly and non-elderly groups of 79 and 68 years, respectively. Patient characteristics, such as age, sex, treatment with antifibrotic agents, and disease severity, based on JRS classification or GAP state, were comparable between the elderly and non-elderly groups (Table 1). According to the disease severity score, the patients with IPF were categorized according to the JRS classification (I/II/III/IV; 38/6/17/20) and GAP models (I/II/III; 39/36/6). Mild disease was predominantly observed in both the elderly and the non-elderly groups.
All data are presented as median (interquartile range). JRS classification and GAP stage include only the available data of 81 patients.
Similarly, the serum levels of KL-6, SP-D, and LDH and the results of respiratory function tests (%FVC, %DLco, and %DLco/VA) were comparable between the elderly and the non-elderly groups (Table 1).
3.1. Analysis of Survival Probabilities
3.1.1. Survival Probabilities of All Enrolled Patients
3.1.2. Survival Probabilities according to Treatment Regimen
Kaplan–Meier analysis of patients administered pirfenidone showed no difference in MST between the elderly (n = 17) (40.3 months) and non-elderly (n = 21) (53.2 months, p = 0.96) groups (Figure 2A). A similar trend was observed for nintedanib-treated patients: elderly (n = 30) (51.0 months) vs. non-elderly (n = 24) (52.6 months, p = 0.94) (Figure 2B).
3.1.3. Survival Probabilities of All Enrolled Patients (n = 91) according to the Status of Successful 1-Year Treatment
Kaplan–Meier analysis showed the survival probabilities of patients with long-term treatment of IPF (n = 40) at 2 and 5 years after initial treatment of 89.0% and 52.4%, respectively, which did not reach the median survival rate (Figure 3).
3.2. Cumulative Incidence Ratios of Acute Exacerbation of IPF
3.2.1. Cumulative Incidence Ratio of Acute Exacerbation of IPF with Long-Term Antifibrotic Agent Use (>1 year) Based on JRS or GAP Stages
Among patients with >1 year of treatment (n = 40), the cumulative incidence ratios of AE of IPF within 1, 2, and 3 years were 15.4%, 26.3%, and 36.0%, respectively (Figure 4A). According to disease severity, mild disease based on JRS classifications I and II (n = 27) showed a lower occurrence of AEs compared to classes III and IV (n = 13) during the observational period; however, the difference was not statistically significant (p = 0.072) (Figure 4B). In contrast, the incidence of AE was significantly lower for GAP stage I (n = 20) compared to GAP stages II and III (n = 20, p = 0.028) during the observational period (Figure 4C).
3.2.2. Cumulative Incidence Ratio of AE of IPF with Long-Term Antifibrotic Agent Use (>1 year) according to the Type of Antifibrotic Agent
Patient characteristics were comparable in terms of sex, age, body mass index, disease severity according to JRS classification or GAP stage, and serum data (except for the %DLco/VA) when comparing between the pirfenidone and nintedanib groups (Table 2).
In the log-rank analysis, the cumulative incidence of AE was significantly higher in the pirfenidone group (n = 25) than that in the nintedanib group (n = 15) (p = 0.005) (Figure 5). The cumulative incidences of AE within 1, 2, and 3 years in the pirfenidone and nintedanib groups were (35.7%, 50%, and 60%) and (4%, 13.1%, and 21%), respectively.
On simple cox regression analysis, use of pirfenidone was associated with a significantly higher risk for AE than that of nintedanib (hazard ratio (HR) 4.757, 95% confidence interval (CI) 1.449–15.613, p = 0.01). The risk of AE was lower in females than in males (HR 0.096, HR 0.011–0.829, p = 0.033). On the other hand, “age” and/or “elderly itself” cannot be significant parameters for predicting AE.
Multiple cox regression analysis showed that the use of pirfenidone was associated with a significantly higher risk of AE compared to nintedanib (HR 5.840, 95% CI 1.311–26.007, p = 0.021), while the risk of AE was lower in female than in male patients (HR 0.091, 95%CI 0.009–0.963, p = 0.046). Age was not a predictive factor for AE (HR 0.974, 95% CI 0.9.9–1.043, p = 0.450).
3.3. Effects of Antifibrotic Agents in Elderly Patients with IPF
Among all elderly IPF patients, the durations from the first visit to initial treatment did not differ significantly between the >1-year and <1-year treatment groups (median 2.0 months, IQR: 0–15.0 months vs. median 6.5 month, IQR: 1.8-–13.3 months, p = 0.193) groups (Table 3). Similarly, the timings for the initiation of treatment with pirfenidone (median 4 months, IQR: 0–11 months) and nintedanib (median 1 month, IQR: 1–16.5 months, p = 0.174) did not differ significantly.
The Kaplan–Meier analysis of elderly patients with IPF (n = 46) showed that prolonged treatment (>1 year) did not affect the survival probability (Figure 6A), the cumulative incidence of AE (Figure 6B), or the total AE. However, according to the type of antifibrotic agents, the incidence of AE was significantly lower in the groups of patients administered nintedanib for >1 year compared to that in patients administered the drug for <1 year (Figure 7A, p = 0.049). This trend was not observed for pirfenidone treatment (Figure 7B).
Cox regression analysis showed that pirfenidone use (HR 2.890, 95% CI 0.845–9.886, p = 0.091) or sex (female) (HR 0.200, 95% CI 0.025–1.565, p = 0.125) were not predictive factors for AE.
The frequencies of adverse effects were comparable between groups administered treatment for >1 and <1 year (Table 3). The adverse events mainly consisted of appetite loss, diarrhea, liver dysfunction, and dysgeusia. Among all adverse effects, grade III or higher severity was observed in only one patient with diarrhea, who discontinued treatment (Table 3). Similarly, the proportions of patients discontinuing and/or reducing the dose of antifibrotic agents did not differ significantly according to treatment duration.
4. Discussion
Although the effects of antifibrotic agents on the prognosis of patients with IPF remain unclear, the results of this study provided real-world evidence that antifibrotic agents prolonged the survival times of patients with IPF compared to previous reports (2, 3), and also showed the beneficial effects even in elderly patients (≥75 years of age). Moreover, the long-term use (>1 year) of antifibrotic agents also showed positive effects on survival probability compared to short-term use (<1 year). This effect was probably due to a decrease in the cumulative incidence of AE, which will enhance the early initiation of antifibrotic agents in mild-stage IPF (JRS classification I and II or GAP stage I).
Natsuizaka et al. [2] reported an MST of patients with IPF patients in Japan of 35 months, while foreign countries reported MSTs ranging from 3 to 5 years [10]. Our real-world data demonstrated that the use of antifibrotic agents prolonged the MST (53 months, calculated from the first visit to our hospital), and did not reach the MST (calculated from the day of initial treatment), suggesting the importance of continuous treatment.
Kang et al. [11] reported that antifibrotic treatment reduced the risks of all-cause mortality, hospitalization (all-cause and respiratory-related), AE, and mortality after AE, but did not refer to the duration of treatment. Dempsey et al. [12] reported that the risk of mortality or hospitalization decreased only during the first 2 years of antifibrotic treatment. Although the most important known prognostic determinants for mortality are declined lung function, acute exacerbations, and pulmonary hypertension, we found that long-term antifibrotic agent use (>1 year) decreased the incidence of AE, which resulted in increased survival probabilities.
We also found that the initiation of antifibrotic agents in early stage IPF accelerated the beneficial effects of AE to prevent a decline in lung function or risk of mortality. Sugino et al. [13] also reported the beneficial effects of antifibrotic agents on %FVC for patients with JRS stage I with oxygen desaturation on the 6 minutes’ walk test or increased GAP staging (II/III). Similarly, Poletti et al. [14] described that the early diagnosis and prompt initiation of antifibrotic therapy for IPF patients preserved lung function 12 months after baseline. Their study enrolled patients with relatively mild-stage IPF, with a mean predicted FVC% of 80.01%, suggesting the importance of the early induction of antifibrotic agents in mild stages. Another study [15] demonstrated the beneficial effect of antifibrotic agents on survival probability in patients with GAP stage > 1, with higher probabilities observed for nintedanib compared to pirfenidone.
In this study, among the 40 patients with long-term treatment, nintedanib showed a more beneficial effect on AE compared to pirfenidone, which might be due to the low DLco/VA at enrollment in the pirfenidone group. However, the beneficial effects on AE were observed even in elderly patients with IPF with prolonged nintedanib use (>1 year). Isshiki et al. [7] reported a significantly lower cumulative incidence of AE for pirfenidone compared to nintedanib. Thus, our data should be cautiously interpreted and confirmed in further prospective studies with larger numbers of patients. Previous studies reported that both nintedanib and pirfenidone can preserve lung function or reduce the risk of mortality compared to non-treated patients [16,17,18,19]. Furthermore, Cameli et al. [20] reported similar effectiveness between pirfenidone and nintedanib in terms of mortality and functional disease progression. However, which drug should be preferred for early initiation in the mild stage is an unresolved critical issue.
This study had several limitations. First, this was a retrospective observational study with a relatively small number of IPF patients. Second, this study was performed at a single center. These factors may limit the generalizability of our results; however, we eliminated patients treated with both nintedanib and pirfenidone and patient management was less variable than that in multicenter cohorts. Third, this study did not describe in detail the adverse events associated with antifibrotic agents. Uchida et al. [21] reported that grade 2 nausea, diarrhea, and emaciation were the most common adverse events of antifibrotic agent use in patients aged ≥ 75 years, while grade 4 was not. The same trend was observed in this study.
This study provided real-world data demonstrating the positive effects of antifibrotic agents use on the survival probability and frequency of AE even in elderly patients. These effects were greater in early stage IPF based on JRS/GAP or with long-term use, which requires confirmation in future studies.
Author Contributions
K.H., T.S. and H.I. conducted the study. K.H. and H.I. analyzed the data. K.H. and T.S. wrote the manuscript draft. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
This present study received human research ethics approval from the Human Ethics Board of the Ethics Committee of Kyorin University Hospital (approval number: 968, H29-044). We ensure the confidentiality of patient data and comply with the Helsinki statement. We ensure all methods were carried out in accordance with the Declaration of Helsinki. Due to the retrospective nature of the study, the Ethics Committee of Kyorin University Hospital determined that no patient consent was required.
Informed Consent Statement
Patient consent for publication is not required.
Data Availability Statement
The data used and/or analyzed in this study are available from the corresponding author on reasonable request. All data generated or analyzed during this study are included in this manuscript, and the database is available from the corresponding author (sara@yd5.so-net.ne.jp) upon reasonable request.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Kondoh, Y.; Suda, T.; Hongo, Y.; Yoshida, M.; Hiroi, S.; Iwasaki, K.; Takeshima, T.; Homma, S. Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis. Respir. Res. 2022, 23, 24. [Google Scholar] [CrossRef] [PubMed]
- Natsuizaka, M.; Chiba, H.; Kuronuma, K.; Otsuka, M.; Kudo, K.; Mori, M.; Bando, M.; Sugiyama, Y.; Takahashi, H. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am. J. Respir. Crit. Care Med. 2014, 190, 773–779. [Google Scholar] [CrossRef] [PubMed]
- Sharif, R. Overview of idiopathic pulmonary fibrosis (IPF) and evidence-based guidelines. Am. J. Manag. Care 2017, 23 (Suppl. S11), S176–S182. [Google Scholar] [PubMed]
- Naccache, J.M.; Jouneau, S.; Didier, M.; Borie, R.; Cachanado, M.; Bourdin, A.; Reynaud-Gaubert, M.; Bonniaud, P.; Israël-Biet, D.; Prévot, G.; et al. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 2022, 10, 26–34. [Google Scholar] [CrossRef]
- Biondini, D.; Balestro, E.; Sverzellati, N.; Cocconcelli, E.; Bernardinello, N.; Ryerson, C.J.; Spagnolo, P. Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF): An overview of current and future therapeutic strategies. Expert Rev. Respir. Med. 2020, 14, 405–414. [Google Scholar] [CrossRef] [PubMed]
- Homma, S.; Suda, T.; Hongo, Y.; Yoshida, M.; Hiroi, S.; Iwasaki, K.; Takeshima, T.; Kondoh, Y. Incidence and changes in treatment of acute exacerbation of idiopathic pulmonary fibrosis in Japan: A claims-based retrospective study. Respir. Investig. 2022, 60, 798–805. [Google Scholar] [CrossRef]
- Isshiki, T.; Sakamoto, S.; Yamasaki, A.; Shimizu, H.; Miyoshi, S.; Nakamura, Y.; Homma, S.; Kishi, K. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience. Respir. Med. 2021, 187, 106551. [Google Scholar] [CrossRef]
- Iwata, T.; Yoshida, S.; Fujiwara, T.; Wada, H.; Nakajima, T.; Suzuki, H.; Yoshino, I. Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients with Idiopathic Pulmonary Fibrosis. Ann. Thorac. Surg. 2016, 102, 1905–1910. [Google Scholar] [CrossRef]
- Raghu, G.; Remy-Jardin, M.; Myers, J.L.; Richeldi, L.; Ryerson, C.J.; Lederer, D.J.; Behr, J.; Cottin, V.; Danoff, S.K.; Morell, F.; et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2018, 198, e44–e68. [Google Scholar] [CrossRef]
- Raghu, G.; Rochwerg, B.; Zhang, Y.; Garcia, C.A.; Azuma, A.; Behr, J.; Brozek, J.L.; Collard, H.R.; Cunningham, W.; Homma, S.; et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2015, 192, e3–e19. [Google Scholar] [CrossRef]
- Kang, J.; Han, M.; Song, J.W. Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: A propensity score matching analysis. Sci. Rep. 2020, 10, 15620. [Google Scholar] [CrossRef] [PubMed]
- Dempsey, T.M.; Sangaralingham, L.R.; Yao, X.; Sanghavi, D.; Shah, N.D.; Limper, A.H. Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 2019, 200, 168–174. [Google Scholar] [CrossRef] [PubMed]
- Sugino, K.; Ono, H.; Watanabe, N.; Ando, M.; Tsuboi, E.; Homma, S.; Kishi, K. Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis. BMC Pulm. Med. 2021, 21, 218. [Google Scholar] [CrossRef] [PubMed]
- Poletti, V.; Vancheri, C.; Albera, C.; Harari, S.; Pesci, A.; Metella, R.R.; Campolo, B.; Crespi, G.; Rizzoli, S.; FIBRONET Study Group C; et al. Clinical course of IPF in Italian patients during 12 months of observation: Results from the FIBRONET observational study. Respir. Res. 2021, 22, 66. [Google Scholar] [CrossRef]
- Gao, J.; Kalafatis, D.; Carlson, L.; Pesonen, I.H.; Li, C.X.; Wheelock, Å.; Magnusson, J.M.; Sköld, C.M. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: A longitudinal analysis of the Swedish IPF Registry. Respir. Res. 2021, 22, 40. [Google Scholar] [CrossRef]
- Brown, A.W.; Fischer, C.P.; Shlobin, O.A.; Buhr, R.G.; Ahmad, S.; Weir, N.A.; Nathan, S.D. Outcomes after hospitalization in idiopathic pulmonary fibrosis: A cohort study. Chest 2015, 147, 173–179. [Google Scholar] [CrossRef]
- Ley, B.; Swigris, J.; Day, B.M.; Stauffer, J.L.; Raimundo, K.; Chou, W.; Collard, H.R. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 2017, 196, 756–761. [Google Scholar] [CrossRef]
- Vianello, A.; Molena, B.; Turato, C.; Braccioni, F.; Arcaro, G.; Paladini, L.; Andretta, M.; Saetta, M. Pirfenidone improves the survival of patients with idiopathic pulmonary fibrosis hospitalized for acute exacerbation. Curr. Med. Res. Opin. 2019, 35, 1187–1190. [Google Scholar] [CrossRef]
- Collard, H.R.; Richeldi, L.; Kim, D.S.; Taniguchi, H.; Tschoepe, I.; Luisetti, M.; Roman, J.; Tino, G.; Schlenker-Herceg, R.; Hallmann, C.; et al. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur. Respir. J. 2017, 49, 1601339. [Google Scholar] [CrossRef]
- Cameli, P.; Refini, R.M.; Bergantini, L.; d’Alessandro, M.; Alonzi, V.; Magnoni, C.; Rottoli, P.; Sestini, P.; Bargagli, E. Long-Term Follow-Up of Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone or Nintedanib: A Real-Life Comparison Study. Front. Mol. Biosci. 2020, 7, 581828. [Google Scholar] [CrossRef]
- Uchida, Y.; Ikeda, S.; Sekine, A.; Tabata, E.; Oda, T.; Okuda, R.; Kitamura, H.; Baba, T.; Komatsu, S.; Ogura, T. Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis. Respir. Investig. 2021, 59, 99–105. [Google Scholar] [CrossRef] [PubMed]
Figure 1.
Survival probabilities based on the Kaplan–Meier method for all enrolled patients: (A) The median survival time (MST) from the first visit to our hospital was 53 months. (B) The MST did not differ between the elderly and non-elderly groups.
Figure 1.
Survival probabilities based on the Kaplan–Meier method for all enrolled patients: (A) The median survival time (MST) from the first visit to our hospital was 53 months. (B) The MST did not differ between the elderly and non-elderly groups.
Figure 2.
Survival probabilities according to the Kaplan–Meier method for patients treated with pirfenidone (A) and nintedanib (B), showing that the mean survival times (MSTs) did not differ between elderly and non-elderly groups in each treatment group.
Figure 2.
Survival probabilities according to the Kaplan–Meier method for patients treated with pirfenidone (A) and nintedanib (B), showing that the mean survival times (MSTs) did not differ between elderly and non-elderly groups in each treatment group.
Figure 3.
Survival probabilities after treatment among patients with IPF and antifibrotic agent use for ≥1 year. The 2- and 5-year survival probabilities (89.0% and 52.4%, respectively) did not reach the median survival rate.
Figure 3.
Survival probabilities after treatment among patients with IPF and antifibrotic agent use for ≥1 year. The 2- and 5-year survival probabilities (89.0% and 52.4%, respectively) did not reach the median survival rate.
Figure 4.
Cumulative incidence ratios of acute exacerbation of IPF. The ratios within 1, 2, and 3 years among patients with long-term antifibrotic agent use (≥1 year, n = 40) were 15.4%, 26.3%, and 36.0%, respectively (A). Patients with mild disease (JRS classifications I and II) showed a lower occurrence of AE compared to those with moderate to severe stages (classes III and IV) (B). Patients with GAP stage I showed a significantly lower incidence of AE compared to those with GAP stages II and III during the observational period (C). * means p value is less than 0.05.
Figure 4.
Cumulative incidence ratios of acute exacerbation of IPF. The ratios within 1, 2, and 3 years among patients with long-term antifibrotic agent use (≥1 year, n = 40) were 15.4%, 26.3%, and 36.0%, respectively (A). Patients with mild disease (JRS classifications I and II) showed a lower occurrence of AE compared to those with moderate to severe stages (classes III and IV) (B). Patients with GAP stage I showed a significantly lower incidence of AE compared to those with GAP stages II and III during the observational period (C). * means p value is less than 0.05.
Figure 5.
Log-rank analysis showed a significantly higher cumulative incidence of AE in the pirfenidone group than that in the nintedanib group. ** means p value is less than 0.01.
Figure 5.
Log-rank analysis showed a significantly higher cumulative incidence of AE in the pirfenidone group than that in the nintedanib group. ** means p value is less than 0.01.
Figure 6.
Log-rank analysis showing comparable survival probabilities between longer (≥1 year) and shorter (<1 year) treatment durations (A). The cumulative incidence of AE is also comparable between two groups (B).
Figure 6.
Log-rank analysis showing comparable survival probabilities between longer (≥1 year) and shorter (<1 year) treatment durations (A). The cumulative incidence of AE is also comparable between two groups (B).
Figure 7.
Treatment-based analysis in elderly patients with IPF. The cumulative incidence of acute exacerbation (AE) in patients administered nintedanib is significantly lower in those with prolonged treatment duration (≥1 year) compared to those with a shorter treatment duration (A). This trend was not observed for pirfenidone treatment (B). * means p value is less than 0.05.
Figure 7.
Treatment-based analysis in elderly patients with IPF. The cumulative incidence of acute exacerbation (AE) in patients administered nintedanib is significantly lower in those with prolonged treatment duration (≥1 year) compared to those with a shorter treatment duration (A). This trend was not observed for pirfenidone treatment (B). * means p value is less than 0.05.
Table 1.
Patient characteristics.
| All Patients (n = 91) | Elderly Group (n = 46) | Non-Elderly Group (n = 45) | p-Value | |
|---|---|---|---|---|
| Gender (male/female) | 63/28 | 32/14 | 31/14 | 1.0 |
| Age | 75 (68–79) | 79 (76–81) | 68 (63–72) | <0.001 *** |
| Comorbidity | ||||
| Malignancy | 17 | 10 | 7 | 0.592 |
| Cardiovascular disease | 7 | 2 | 5 | 0.267 |
| Diabetes mellitus | 15 | 9 | 6 | 0.574 |
| COPD | 6 | 2 | 4 | 0.434 |
| JRS classification (I/II/III/IV) | (38/6/17/20) | (17/5/6/10) | (21/1/11/10) | 1 |
| GAP stage (I/II/III) | (39/36/6) | (16/22/2) | (23/14/4) | 0.141 |
| Duration from 1st visit to initial therapy (month) | 6 (1–17) | 4 (1–13) | 8 (3–25) | 0.123 |
| Pirfenidone/Nintedanib | 37/54 | 16/30 | 21/24 | 0.29 |
| KL-6 (IU/mL) | 1004 (644–1745) | 816 (500–1957) | 868 (465–1342) | 0.948 |
| SP-D (ng/mL) | 249 (165–358) | 207 (142–388) | 209 (143–353) | 0.378 |
| BMI | 23.4 (20.9–25.9) | 22.8 (21.1–24.9) | 24.9 (21.7–28.6) | 0.07 |
| Alb (g/dL) | 4.1 (3.9–4.4) | 4.1 (3.8–4.4) | 4.2 (3.9–4.4) | 0.238 |
| LDH (U/mL) | 233 (201–262) | 222 (201–254) | 215 (197–265) | 0.984 |
| %FVC | 75.2 (61.3–88.3) | 76.8 (61.0–85.5) | 81.8 (58.4–94.5) | 0.824 |
| %DLco | 54.1 (40.8–71.8) | 55.4 (41.5–70.1) | 57.7 (40.8–80.9) | 0.898 |
| %DLco/VA | 69.7 (48.5–83.8) | 68.9 (53.1–83.5) | 76.8 (51.2–90.6) | 0.501 |
*** means p value is less than 0.001.
Table 2.
Patient characteristics of successful long-term antifibrotic treatments.
| All Patients (n = 40) | Pirfenidone (n = 15) | Nintedanib (n = 25) | p-Value | |
|---|---|---|---|---|
| Gender (male/female) | 28/12 | 10/5 | 18/7 | 0.736 |
| Age | 75 (67–79) | 68 (56–75) | 76 (67–81) | 0.737 |
| BMI | 23.9 (22.3–26.9) | 24.9 (23.8–43.6) | 23.3 (21.2–26.4) | 0.371 |
| JRS classification (I–II/III–IV) | (27/13) | (8/7) | (19/6) | 0.175 |
| GAP stage (I/II–III) | (20/20) | (6/9) | (14/11) | 0.514 |
| Duration from 1st visit to initial treatment (month) | 6.0 (1.0–16.0) | 6.0 (0–19.0) | 6.0 (2.0–15.0) | 0.510 |
| KL-6 (IU/mL) | 956 (576–1445) | 748 (395–1479) | 868 (540–1186) | 0.410 |
| SP-D (ng/mL) | 209 (142–311) | 146 (138–323) | 191 (137–266) | 0.808 |
| Alb(g/dL) | 4.1 (3.9–4.3) | 4.1 (3.8–4.3) | 4.0 (3.9–4.4) | 0.676 |
| LDH (U/mL) | 217 (198–246) | 208 (187–234) | 212 (200–235) | 0.806 |
| %FVC | 73.4 (61.7–87.5) | 81.8 (53.6–93.8) | 77.4 (60.3–103.8) | 0.530 |
| %DLco | 55.5 (46.5–70.1) | 62.8 (51.2–77.7) | 58.9 (48.0–70.2) | 0.365 |
| %DLco/VA | 76.7 (52.5–86.3) | 70.9 (46.1–94.2) | 80.9 (63.8–89.9) | 0.038 * |
All data are presented as median (interquartile range). * means p value is less than 0.05.
Table 3.
Characteristics of elderly patients with or without long-term treatment with antifibrotic agents.
Table 3.
Characteristics of elderly patients with or without long-term treatment with antifibrotic agents.
| Over 1 Year Tx | Less than 1 Year Tx | p Value | |
|---|---|---|---|
| Number of patients | 20 | 26 | |
| Male | 12 | 19 | 0.333 |
| Age (years) | 79.5 (76.0–81.0) | 78.0 (77.0–79.3) | 0.180 |
| JRS classification (Ⅰ/Ⅱ/Ⅲ/Ⅳ) | 9/3/1/5 | 10/3/5/5 | 0.561 a |
| GAP stage (Ⅰ/Ⅱ/Ⅲ) | 7/13/0 | 8/18/0 | 1.0 b |
| Comorbidity | |||
| Malignancy | 3 | 7 | 0.476 |
| lung cancer | 1 | 1 | |
| prostate cancer | 1 | 2 | |
| lymphoma | 1 | 0 | |
| rectal cancer | 0 | 1 | |
| gastric cancer | 0 | 1 | |
| renal cell cancer | 0 | 1 | |
| unknown | 0 | 1 | |
| Cardiovascular disease | 0 | 2 | 0.498 |
| Diabetes mellitus | 5 | 4 | 0.472 |
| COPD | 0 | 2 | 0.498 |
| Pirfenidone/Nintedanib | 6/14 | 11/15 | 0.534 |
| Duration of antifibrotic Tx (months) | 24.5 (18.0–34.3) | 5.0 (2.3–7.8) | 0.001 |
| AE | 4 | 7 | 0.728 |
| Number of AEs after Tx | |||
| Duration of initial treatment to AE (months) | 34.5 (24.3–41.0) | 13.5 (7.0–26.5) | <0.001 |
| Adverse effects | 5 (1) | 8 (0) | 0.749 |
| appetite loss | 2 | 4 | 0.684 |
| diarrhea | 2 (1) | 3 | 1.0 |
| liver dysfunction | 1 | 0 | 0.435 |
| dysgeusia | 0 | 2 | 0.498 |
| Discontinuation of Tx | 3 | 5 | 1.0 |
| Dose reduction of Tx | 2 | 3 | 1.0 |
All data are presented as median with interquartile range. Both “over 1 year Tx” and “less than 1 year Tx” groups have unknown cases (n = 2 and n = 3) for JRS classification. “a” means JRS classification I/II vs. III/IV, “b” means GAP stage I vs. II/III. AE: acute exacerbation, Tx: therapy, parentheses means number of grade 3. JRS: Japanese respiratory society. GAP: Gender, Age, and Physiology. COPD: chronic obstructive pulmonary disease.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Honda, K.; Saraya, T.; Ishii, H. A Real-World Prognosis in Idiopathic Pulmonary Fibrosis: A Special Reference to the Role of Antifibrotic Agents for the Elderly. J. Clin. Med. 2023, 12, 3564. https://doi.org/10.3390/jcm12103564
AMA Style
Honda K, Saraya T, Ishii H. A Real-World Prognosis in Idiopathic Pulmonary Fibrosis: A Special Reference to the Role of Antifibrotic Agents for the Elderly. Journal of Clinical Medicine. 2023; 12(10):3564. https://doi.org/10.3390/jcm12103564
Chicago/Turabian StyleHonda, Kojiro, Takeshi Saraya, and Haruyuki Ishii. 2023. "A Real-World Prognosis in Idiopathic Pulmonary Fibrosis: A Special Reference to the Role of Antifibrotic Agents for the Elderly" Journal of Clinical Medicine 12, no. 10: 3564. https://doi.org/10.3390/jcm12103564
APA StyleHonda, K., Saraya, T., & Ishii, H. (2023). A Real-World Prognosis in Idiopathic Pulmonary Fibrosis: A Special Reference to the Role of Antifibrotic Agents for the Elderly. Journal of Clinical Medicine, 12(10), 3564. https://doi.org/10.3390/jcm12103564
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
